Virologic Outcomes After Long-Acting Antiretroviral Therapy Initiation With and Without Viremia in 2 Large US Clinic Cohorts

Clinical Infectious Diseases 2026 Open access

Read full text
Authors: Matthew Spinelli, Megan J. Heise, David V. Glidden, Janet Grochowski, Jon Oskarsson, Larisa Niles-Carnes, Eudiah Ochieng, Meredith Lora, Amalia Aldredge, Nathanael Gistand, Chesa Cox, Jonathan Colasanti
+2 more Monica Gandhi, Lauren F. Collins
DOI: 10.1093/cid/ciag392
Cited by: 3
References: 10

Abstract

Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.

Fields of Study & Subjects

HIV/AIDS Research and Interventions HIV/AIDS drug development and treatment HIV Research and Treatment

Publication details

Journal / source
Clinical Infectious Diseases
Publisher
Oxford University Press (OUP)
Publication date
29 June 2026
Language
EN